Literature DB >> 25848924

Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease.

David T Rubin1,2, Noa Krugliak Cleveland1,3.   

Abstract

The doctor-patient relationship (DPR) in inflammatory bowel disease (IBD) has been facing new challenges, in part due to the substantial progress in medical and surgical management and also due to the rapid expansion of patient access to medical information. Not surprisingly, the complexity of IBD care and heterogeneity of the disease types may lead to conflict between a physician's therapeutic recommendations and the patient's wishes. In this commentary, we propose that the so-called "treat-to-target" approach of objective targets of disease control and serial adjustments to therapies can also strengthen the DPR in IBD by enabling defined trials of alternative approaches, followed by a more objective assessment and reconsideration of treatments. We contend that such respect for patient autonomy and the use of objective markers of disease activity improves the DPR by fostering trust and both engaging and empowering patients and physicians with the information necessary to make shared decisions about therapies.

Entities:  

Mesh:

Year:  2015        PMID: 25848924     DOI: 10.1038/ajg.2015.86

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

Review 1.  Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.

Authors:  Barrett G Levesque; William J Sandborn; Joannie Ruel; Brian G Feagan; Bruce E Sands; Jean-Frederic Colombel
Journal:  Gastroenterology       Date:  2014-08-13       Impact factor: 22.682

Review 2.  Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.

Authors:  R V Bryant; S Winer; S P L Travis; R H Riddell
Journal:  J Crohns Colitis       Date:  2014-09-27       Impact factor: 9.071

Review 3.  Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options.

Authors:  Corey A Siegel
Journal:  Gut       Date:  2011-12-20       Impact factor: 23.059

Review 4.  What do changes in inflammatory bowel disease management mean for our patients?

Authors:  Subrata Ghosh; Geert D'Haens; Brian G Feagan; Mark S Silverberg; Eva M Szigethy
Journal:  J Crohns Colitis       Date:  2012-02       Impact factor: 9.071

5.  Sins of omission: getting too little medical care may be the greatest threat to patient safety.

Authors:  Rodney A Hayward; Steven M Asch; Mary M Hogan; Timothy P Hofer; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

Review 6.  Review article: explaining risks of inflammatory bowel disease therapy to patients.

Authors:  C A Siegel
Journal:  Aliment Pharmacol Ther       Date:  2010-10-26       Impact factor: 8.171

7.  Understanding how patients (vs physicians) approach the decision to escalate treatment: a proposed conceptual model.

Authors:  Liana Fraenkel; Elizabeth K Seng; Meaghan Cunningham; Kristin Mattocks
Journal:  Rheumatology (Oxford)       Date:  2014-08-28       Impact factor: 7.580

8.  Do increases in patient activation result in improved self-management behaviors?

Authors:  Judith H Hibbard; Eldon R Mahoney; Ronald Stock; Martin Tusler
Journal:  Health Serv Res       Date:  2007-08       Impact factor: 3.402

Review 9.  Definition and evaluation of mucosal healing in clinical practice.

Authors:  Silvia Mazzuoli; Francesco W Guglielmi; Elisabetta Antonelli; Marianna Salemme; Gabrio Bassotti; Vincenzo Villanacci
Journal:  Dig Liver Dis       Date:  2013-08-07       Impact factor: 4.088

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

View more
  11 in total

1.  When Should Therapy for Inflammatory Bowel Disease Be Stopped?

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-06

2.  Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service.

Authors:  Seth Ian Squires; Allan John Boal; Selina Lamont; Graham D Naismith
Journal:  Frontline Gastroenterol       Date:  2017-03-29

3.  Notable gaps between patients' and physicians' perspectives on communication and disease management in Japan: multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care.

Authors:  Kenji Watanabe; Sean Gardiner; Shoko Arai
Journal:  Therap Adv Gastroenterol       Date:  2022-06-14       Impact factor: 4.802

4.  Factors Predicting the Adherence to the Therapy of Italian IBD Patients.

Authors:  Cristina Bucci; Fabiana Zingone; Stella Tammaro; Paola Iovino; Antonella Santonicola; Carolina Ciacci
Journal:  Gastroenterol Res Pract       Date:  2017-08-07       Impact factor: 2.260

5.  Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits.

Authors:  David T Rubin; Marla C Dubinsky; Steve Martino; Kathleen A Hewett; Julian Panés
Journal:  Inflamm Bowel Dis       Date:  2017-04       Impact factor: 5.325

6.  Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views.

Authors:  Susan J Connor; Alexandra Sechi; Mauricio Andrade; J Jasper Deuring; David Witcombe
Journal:  JGH Open       Date:  2021-08-14

7.  JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.

Authors:  Rui Zhou; Ying Chang; Jing Liu; Min Chen; Hongling Wang; Meifang Huang; Shi Liu; Xiaobing Wang; Qiu Zhao
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

8.  How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study.

Authors:  Yonghui Ma; Jinqiu Yang; Bota Cui; Hongzhi Xu; Chuanxing Xiao; Faming Zhang
Journal:  BMC Med Ethics       Date:  2017-05-31       Impact factor: 2.652

9.  Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View.

Authors:  Marla C Dubinsky; Kenji Watanabe; Pauliina Molander; Laurent Peyrin-Biroulet; Michele Rubin; Gil Y Melmed; J Jasper Deuring; John Woolcott; Joseph C Cappelleri; Kathy Steinberg; Susan Connor
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

10.  Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians.

Authors:  David T Rubin; Ailsa Hart; Remo Panaccione; Alessandro Armuzzi; Ulla Suvanto; J Jasper Deuring; John Woolcott; Joseph C Cappelleri; Kathy Steinberg; Laura Wingate; Stefan Schreiber
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.